Suboptimal inhibition of platelet aggregation following tirofiban bolus in patients undergoing percutaneous coronary intervention for unstable angina pectoris

American Journal of Cardiology

Volumn 91, Issue 7, 2003, Pages 872-875

  Soffer, Daniel ^a   Moussa, Issam ^b   Karatepe, Murat ^b   Harjai, Kishore J ^b   Boura, Judith ^b   Dixon, Simon R ^b   Grines, Cindy L ^b   O'Neill, William W ^b   Roubin, Gary S ^b   Moses, Jeffrey W ^b  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FIBRINOLYTIC THERAPY; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0037378877     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00024-9     Document Type: Article

References (11)

1. Kereiakes D.J., Kleiman N.S., Ambrose J., Cohen M., Rodriguez S., Palabrica T., Herrmann H.C., Sutton J.M., Weaver W.D., McKee D.B., Fitzpatrick V., Sax F.L. Randomized, double-blind, placebo-controlled dose ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol. 27:1996;536-542.
2. Effect of platelet glycoprotein IIb/IIIa blockade with tirofiban on advers cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 96:1997;1445-1453.
3. Topol E.J., Moliterno D.J., Herrmann H.C., Powers E.R., Grines C.L., Cohen D.J., Cohen E.A., Bertrand M., Neumann F.J., Stone G.W., DiBattiste P.M., Demopoulos L. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization, for the TARGET investigators. N Engl J Med. 344:2001;1888-1894.
4. Braunwald E. Unstable angina a classification . Circulation. 80:1989;410-414.
5. ™ point-of-care hematology analyzer. J Extracorporeal Technol. 30:1998;171-176.
6. Lakkis N.M., George S., Thomas E., Ali M., Guyer K., Carville D. Use of ICHOR-platelet works to assess platelet function in patients treated with GPIIb/IIIa inhibitors. Cathet Cardiovasc Intervent. 53:2001;346-351.
7. Tcheng J.E., Ellis S.G., George B.S., Kereiakes D.J., Kleiman N.S., Talley J.D., Wang A.L., Weisman H.F., Califf R.M., Topol E.J. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody fab 7E3 in high-risk coronary angioplasty. Circulation. 90:1994;1757-1764.
8. Simoons M.L., Jan de Boer M., van den Brand M.J.B.M., van Miltenburg A.J.M., Hoorntje J.C.A., Heyndrickx G.R., van der Wieken L.R., De Bono D., Rutsch W., Schaible T.F., et al. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation. 89:1994;596-603.
9. Soffer D., O'Neill W.W., Harjai K.J., Dixon S.R., Boura J.A., Safian R.D., Grines C.L., Moussa I., Roubin G.S., Moses J.W. Inter-assay variability in the degree of platelet inhibition following GPIIb/IIIa receptor blockade in patients undergoing coronary intervention a comparison of three different point-of-care assays (abstr) . J Am Coll Cardiol. 39:(suppl A):2002;72A.
10. Kereiakis D.J., Broderick T.M., Roth E.M., Whang D., Shimshak T., Runyon J.P., Hattemer C., Schneider J., Lacock P., Mueller M., Abbottsmith C.W. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Am J Cardiol. 84:1999;391-395.
11. Stone G.W., Moliterno D.J., Bertrand M., Neumann F.J., Hermann H.C., Powers E.R., Grines C.L., Cohen D.J., Cohen E.A., Cohen M., Piedmonte M., DiBattiste P.M. Impact of clinical syndrome acuity on the differential response to two glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting the TARGET trial . Circulation. 105:2002;2347-2354.